Lenacapavir Oral

Contraindicated

Lenacapavir Oral Apalutamide Erleada Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Carbamazepine Carbatrol Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Colchicine Colcrys Increased colchicine exposure and an increased risk of colchicine toxicity Details Lenacapavir Oral Encorafenib Braftovi Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Lenacapavir Oral Enzalutamide Xtandi Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Fosphenytoin Cerebyx Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Ivosidenib Tibsovo Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Lomitapide Increased lomitapide exposure Details Lenacapavir Oral Lumacaftor Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Mitotane Lysodren Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Phenytoin Dilantin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Rifampin Rifadin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Rifapentine Priftin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral St John's Wort Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details

Major

Lenacapavir Oral Abemaciclib Verzenio Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Acalabrutinib Calquence Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Afatinib Gilotrif Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Oral Alfentanil Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Aliskiren Tekturna Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Oral Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Lenacapavir Oral Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Lenacapavir Oral Apixaban Eliquis Increased apixaban exposure and increased risk of bleeding Details Lenacapavir Oral Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Lenacapavir Oral Atazanavir Reyataz Increased lenacapavir exposure, increased atazanavir exposure and an increased risk of atazanavir-related adverse reaction Details Lenacapavir Oral Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Lenacapavir Oral Atogepant Qulipta Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Avanafil Stendra Increased sensitive CYP3A substrate exposure Details Lenacapavir Oral Avapritinib Ayvakit Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Benzhydrocodone Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Betrixaban Bevyxxa® Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Oral Bosentan Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Bosutinib Bosulif Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Brexpiprazole Rexulti Increased brexpiprazole exposure Details Lenacapavir Oral Budesonide Entocort Increased sensitive CYP3A substrate exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Oral Buprenorphine Belbuca Increased or reduced buprenorphine exposure Details Lenacapavir Oral Buspirone Bucapsol Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Oral Cariprazine Vraylar Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Lenacapavir Oral Cenobamate Xcopri Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Oral Cobicistat Tybost Increased lenacapavir exposure Details